特异性肝癌细胞结合单链抗体的筛选及克隆表达

用人肝癌细胞系SMMC7721免疫小鼠,提取脾细胞总RNA,构建单链抗体库,从中筛选到1个与人肝癌细胞系HepG2特异性结合的噬菌体－单链抗体。此单链抗体与HepG2细胞结合滴度比正常肝细胞低100倍以上。构建表达质粒pTrx-scFv5-56,单链抗体scFv5-56在大肠杆菌BL21（DE3）中成功地进行了可溶性表达。     

肝癌特异性鼠源及人源化单链抗体基因的构建及大肠杆菌中的表达

为探讨一株肝细胞癌特异性鼠源及其人源化单链抗体基因在大肠杆菌中的可溶性表达策略并比较二者对抗原的结构能力,在三种载体中分别以融合、分泌及胞内表达的方式进行了研究,表达产物均以包涵体形式存在;对复性后的单链抗体以细胞ＥＬＩＳＡ及竞争抑制流式细胞仪法进行检测,表明人源化单链抗体和鼠源单链抗体有相近的抗原结合能力。结论是：大肠杆菌中表达的基因工程单链抗体的可溶性可能主要由自身氨基酸一级序列决定;先前的设     

单链抗体展示系统研究进展

单链抗体(single chain antibody fragment,scFv)是由抗体重链可变区(variable region of heavy chain,VH)和轻链可变区(variable region of light chain,VL)通过柔性短肽连接组成的小分子,是具有完整抗原结合活性的最小功能片段,包含抗体识别及抗原结合部位。相比于其他抗体,scFv具有分子量小、穿透性强、免疫原性弱、易构建表达等优点。目前,scFv最常用的展示系统主要有噬菌体展示系统、核糖体展示系统、mRNA展示系统、酵母细胞表面展示系统和哺乳动物细胞展示系统等。近年来,随着scFv在医学、生物学、食品安全学等领域的发展,使得其在生物合成和应用研究方面备受关注。本文对近年来scFv展示系统的研究进展作一综述,以期为scFv的筛选及应用提供理论基础。     

噬菌体展示技术构建和表达抗人整合素β1单链Fv抗体

整合素（Integrins）是细胞膜蛋白的组成成分,它们是一类细胞粘附分子,并与形态形成的调节密切相关。整合素在细胞与细胞之间,细胞与基质之间的粘附中发挥着重要的作用。本研究通过选择使用鼠抗人整合素β1抑止性单克隆抗体和刺激性单克隆抗体,利用噬菌体展示,成功地构建了单链Fv抗体（scFv）,并对其与整合素β1的结合,选择最佳的可溶性抗体的生产条件等诸方面,进行了应用性研究,同时,也应用链转换（Chain shuffling）试图改变抗体亲和力进行了探索性的试验。     

抗TNF-α单链抗体噬菌体展示文库的建立和鉴定

应用噬菌体展示技术构建抗肿瘤坏死因子α(tumornecrosis factor α,TNF-α)单链抗体(single chain Fv,scFv)文库,从中筛选抗TNF-αscFv并进行鉴定.利用重组人TNF-α(rhTNF-α)免疫小鼠,分别扩增小鼠VH和VL基因,经重叠延伸反应将VH和VL基因拼接成scFv基因,以SfiⅠ/NotⅠ位点定向插入pCANTAB 5E噬菌粒载体,转化E.coli TG1,构建了库容为4.6×108的抗TNF-α单链抗体库.对抗体库进行3轮富集筛选后,ELISA检测阳性克隆的抗原特异性,取1株阳性克隆进行测序分析.结果表明,抗TNF-αscFv基因序列长774bp,编码258个氨基酸.将此阳性克隆转化E.coliHB2151,IPTG诱导可溶性scFv的表达,经SDS-PAGE和Western印迹分析,scFv的分子量约为28kD.经亲和纯化后的scFv可与rhTNF-α结合,并可中和由rhTNF-α引起的L929细胞毒性.本文利用噬菌体抗体库筛选到了高亲和力的抗TNF-αscFv,为研制临床免疫治疗的新型抗体奠定了实验基础.     

噬菌体单链抗体文库的构建及筛选

噬菌体抗体是继多克隆抗体、单克隆抗体之后兴起的第3代基因工程抗体.噬菌体抗体库技术是抗体基因文库技术和噬菌体表面展示技术相结合形成的一项新技术与方法,在生物科学领域极具潜力.现主要就近年来该技术在抗体基因扩增、抗体库的构建、筛选方法等方面的进展进行综述.     

噬菌体抗体库的优化

噬菌体抗体组合文库技术作为噬菌体展示和抗体组合文库两种技术的集成,由于它具有库容量大、特异性高、和敏感性强的优点而被誉为抗体技术的第三次革命。但是由于一些技术上的原因,使得它无法得到广泛的应用,本文就其优化进行综述。     

抗HBsAg人源单链可变区抗体的筛选与可溶性抗体的表达

采用噬菌体表达展示技术,以从乙型肝炎病毒（HBV）表达抗原（HBsAg）阳性血汪有超速离心纯化的HBsAg为固相抗原,从噬菌体单链可变区半合成抗体库中经过5轮“吸附－洗脱－扩增”筛选过程,获得特异性较强的HBsAg人源单链可变区抗体（ScFv）克隆并提取质粒,经SfiⅠ/NotⅠ酶切鉴定后,亚克隆到pCANTAB5E表达载体中,转化大肠杆菌XL1－Blue。经IPTG诱导后,表达的可溶性HBsAg特异性ScFv以50％硫酸胺沉淀,经SDS－PAGE电泳表明,XL1－Blue中表达的HBsAg可溶性ScFv的分子量约28kD。免疫活性检测结果表明,该单链抗体具有较强的抗原结合性和特异性。HBsAg人源单链抗体的筛选和表达成功,为今后HBsAg人源抗体的研究和应用奠定了基础。     

Generation and characterization of C305, a murine neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA

B-lymphocyte stimulator (BLyS) is a member of the tumor necrosis factor (TNF) family and a key regulator of B cell response. Neutralizing single-chain fragment variable (scFv) antibody against BLyS binding to its receptor BCMA has the potential to play a prominent role in autoimmune disease therapy. A phage display scFv library constructed on pill protein of MI 3 filamentous phage was screened using BLyS.After five rounds of panning, their binding activity was characterized by phage-ELISA. Nucleotide sequencing revealed that at least two different scFv gene fragments (C305 and D416) were obtained. The two different scFv gene fragments were expressed to obtain the soluble scFv antibodies, then the soluble scFv antibodies were characterized by means of competitive ELISA and in vitro neutralization assay. The results indicated that C305 is the neutralizing scFv antibody that can inhibit BLyS binding to its receptor BCMA.     

Identification of single-chain antibody fragments specific against SARS-associated coronavirus from phage-displayed antibody library

To develop early diagnostic reagents, effective vaccines, and even drugs against SARS-associated coronavirus (SARS-CoV), the human single fold single-chain antibody fragments, (scFv) libraries I+J (Tomlinson I+J) were used to identify novel scFvs, which can specifically bind to SARS-CoV. Interestingly, two scFvs (B5 and B9) exhibited higher binding specificity to SARS-CoV with the OD(450) value 0.608 and 0.545, respectively, and their coding sequences shared the identical sequence composed of V(H) gene (351bp) and V(L) gene (327bp), so the two scFvs were uniformly named as SA59B and chosen for further analysis. SA59B scFv was expressed in soluble form in Escherichia coli HB2151 and purified by immobilized metal affinity chromatography. The soluble 30kDa SA59B scFv-antibody was verified in SDS-PAGE and Western-blot. The purified SA59B scFv-antibody was labeled with HRP by the glutaraldehyde method, and the concentration of HRP and SA59B scFv-antibody in the SA59B-HRP solution reached 2.4 and 2.28mg/ml, respectively. Then, the binding ability of SA59B-HRP to SARS-CoV was evaluated by ELISA with S/N of 11.6, indicating higher binding specificity between them. Finally, both the SA59B sequence specificity and its application for diagnosis, prophylaxis or therapy of SARS were discussed.     

Recombinant scFv antibodies against E protein and N protein of severe acute respiratory syndrome virus

Severe acute respiratory syndrome (SARS) brought aglobal outbreak in spring of 2003 [1–3], and more andmore attention has been paid on it when a new caseresurfaced in Singapore last September [4]. By the endof May in 2003, WHO reported a cumulative total of 8202infected cases with 725 deaths from 28 countries.Because of the high transmission and morality rate ofSARS, scientists in many countries have made theirefforts in studying SARS coronavirus (SARS-CoV)[5, 6]. Several genomes of…     

人源抗ICAM-1单链抗体的制备及其生物学活性鉴定

利用噬菌体展示技术筛选特异性人源抗ICAM-1单链抗体（Anti-human ICAM-1 scFv）并进行生物学活性鉴定。应用Tomlinson I+J噬菌体抗体库,以P1抗原肽为包被抗原,经过4轮“吸附-洗脱-扩增”进行亲和富集筛选。以PCR反应、ELISA抗原交叉反应和Dot blotting实验进行阳性克隆的鉴定。scFv经原核表达和分离纯化后,以Western blotting实验、竞争ELISA实验和细胞黏附抑制实验对其生物学活性进行初步鉴定。Tomlinson I+J噬菌体抗体库经4轮亲和富集筛选,利用ELISA方法成功筛出4株阳性克隆。通过PCR鉴定反应、ELISA抗原交叉反应和Dot blotting实验,最终获得了1株既能与P1抗原肽特异结合又能与人ICAM-1抗原特异结合的阳性克隆J-A1。对scFv进行原核表达和亲和层析后获得了高纯度的目的蛋白。竞争ELISA实验和细胞黏附抑制实验证实纯化的scFv具有良好的亲和活性和抗细胞黏附活性。文中成功利用噬菌体展示技术筛选到特异性人源抗ICAM-1 scFv,为进一步探索该抗体在炎症相关性疾病治疗中的应用奠定了基础。     

Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen

The Thomsen-Friedenreich disaccharide (TF) is a promising target antigen for tumor immunotherapy, since it is almost exclusively expressed in carcinoma tissues. The TF-specific antibodies generated so far are IgMs of mouse origin with limited therapeutic potential. Phage-displayed scFv repertoires are an established source for recombinant antibodies; however, we were unable to identify scFvs binding to TF when applying libraries in the standard monovalent display format of phagemid systems. Here, we report on the successful selection of TF-specific antibody fragments using a multivalent scFv phagemid library format based on shortened linkers (one amino acid residue). The libraries were constructed from mice immunized with asialoglycophorin and selected using TF displayed on two different carrier molecules in combination with the proteolytically cleavable helper phage KM13. All isolated clones encoded the same framework genes and the same complementarity-determining regions. After affinity maturation only scFv with the founder sequence were selected from secondary repertoires. This indicates a very narrow sequence window for TF-specific antibodies. Investigating other linker-length formats revealed a clear inverse correlation between linker length and binding activity both as soluble proteins and displayed on phages. The highest affinity was obtained with the tetrameric format. The selected scFv was specific for TF on various carrier molecules and tumor cells and performed well in ELISA and immunohistochemistry. We postulate that scFv phagemid library formats with short linkers (i.e. multimeric scFvs) may, in general, be advantageous in selections for the generation of scFvs against carbohydrate epitopes or other epitopes associated with low intrinsic affinity per binding site), and expect that they will be superior in applications for diagnosis or therapy.     

原核系统可溶性表达策略

获得大量目的蛋白的最简单最经济的方法是利用原核表达系统表达外源基因.但由于原核系统的自身特点,使所表达的蛋白常常形成无活性的包涵体.多年来世界各国的研究为解决这一问题尝试了多种方法.本简单介绍原核表达系统的特点及提高蛋白可溶性表达的常用方法.     

Construction of a large synthetic human scFv library with six diversified CDRs and high functional diversity

Antibody phage display provides a powerful and efficient tool for the discovery and development of monoclonal antibodies for therapeutic and other applications. Antibody clones from synthetic libraries with optimized design features have several distinct advantages that include high stability, high levels of expression, and ease of downstream optimization and engineering. In this study, a fully synthetic human scFv library with six diversified CDRs was constructed by polymerase chain reaction assembly of overlapping oligonucleotides. In order to maximize the functional diversity of the library, a β-lactamase selection strategy was employed in which the assembled scFv gene repertoire was fused to the 5′-end of the β-lactamase gene, and in-frame scFv clones were enriched by carbenicillin selection. A final library with an estimated total diversity of 7.6 × 10⁹, greater than 70% functional diversity, and diversification of all six CDRs was obtained after insertion of fully randomized CDR-H3 sequences into this proofread repertoire. The performance of the library was validated using a number of target antigens, against which multiple unique scFv sequences with dissociation constants in the nanomolar range were isolated.     

从大容量噬菌体抗体库中筛选抗DNA-PKcs单链抗体

目的：从单链大容量噬菌体抗体库中筛选特异性的抗DNA-PKcs的人源抗体,用于肿瘤治疗或诊断目的。方法：经抗原性分析及BLAST比对,选定人DNA-PKcs蛋白中抗原性高且与其他蛋白没有同源性的片段,进行原核表达及纯化后将其固定在抗原管上,通过4轮“吸附－洗脱－扩增”过程从大容量抗体库中筛选特异性抗体,转化HB2151菌,制备抗DNA-PKcs的可溶性单链抗体;ELISA检测抗原-抗体结合活性。结果：经生物信息学分析,确定抗原性高且与其他蛋白没有同源性的DNA-PKcs片段DPK3（250个AA）、DPK4（257个AA）。经过4轮筛选,获得26个特异性结合DPK3及31个特异结合DPK4的克隆,指纹分析分别有5种和21种不同的可变区片段;成功制备了可溶性抗体。并做了抗原结合活性鉴定。结论：利用单链大容量抗体库获得抗DNA-PKcs的噬菌体抗体基因并且成功制备成可溶性抗体,为今后的研究和应用奠定了基础。     

Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2

BCF2, a monoclonal antibody raised against scorpion toxin Cn2, is capable of neutralizing both, the toxin and the whole venom of the Mexican scorpion Centruroides noxius Hoffmann. The single chain antibody fragment (scFv) of BCF2 was constructed and expressed in Escherichia coli. Although its affinity for the Cn2 toxin was shown to be in the nanomolar range, it was non-neutralizing in vivo due to a low stability. In order to recover the neutralizing capacity, the scFv of BCF2 was evolved by error-prone PCR and the variants were panned by phage display. Seven improved mutants were isolated from three different libraries. One of these mutants, called G5 with one mutation at CDR1 and another at CDR2 of the light chain, showed an increased affinity to Cn2, as compared to the parental scFv. A second mutant, called B7 with a single change at framework 2 of heavy chain, also had a higher affinity. Mutants G5 and B7 were also improved in their stability but they were unable to neutralize the toxin. Finally, we constructed a variant containing the changes present in G5 and B7. The purpose of this construction was to combine the increments in affinity and stability borne by these mutants. The result was a triple mutant capable of neutralizing the Cn2 toxin. This variant showed the best affinity constant (KD=7.5x10(-11) M), as determined by surface plasmon resonance (BIAcore). The k(on) and k(off) were improved threefold and fivefold, respectively, leading to 15-fold affinity improvement. Functional stability determinations by ELISA in the presence of different concentrations of guanidinium hydrochloride (Gdn-HCl) revealed that the triple mutant is significantly more stable than the parental scFv. These results suggest that not only improving the affinity but also the stability of our scFv were important for recovering its neutralization capacity. These findings pave the way for the generation of recombinant neutralizing antisera against scorpion stings based on scFvs.